Jpmorgan Chase & CO Bio Xcel Therapeutics, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BTAI
# of Institutions
74Shares Held
7.2MCall Options Held
101KPut Options Held
205K-
Armistice Capital, LLC New York, NY2.99MShares$1.91 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA970KShares$621,0750.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$282,0380.0% of portfolio
-
Geode Capital Management, LLC Boston, MA267KShares$170,7000.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA204KShares$130,3130.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $17.9M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...